Pharmaceutical

Novo to buy Catalent: the backlash begins

Novo Nordisk’s plans to buy Catalent has raised objections related to the risk of drug shortages, manufacturing standards, and antitrust violations.

Feb 10, 2024 - 18:00
Novo to buy Catalent: the backlash begins
Novo Nordisk’s plans to buy Catalent has raised objections related to the risk of drug shortages, manufacturing standards, and antitrust violations.
Read the original article

Tags:

Previous Article

Another recall: does Philips have a quality control problem?

Next Article

Pharma and biotech concerned about the stability of large CROs, survey finds

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Genprex’s Reqorsa gene therapy secures another FDA fast-track designation

Genprex’s Reqorsa gene therapy secures another FDA fast...

Jun 29, 2023

Pulse oximeters’ inaccuracies in darker-skinned people require urgent action, AGs tell FDA

Pulse oximeters’ inaccuracies in darker-skinned people ...

Nov 7, 2023

Doctors call out ableism in cancer care: ‘The biggest accommodation is attitude’

Doctors call out ableism in cancer care: ‘The biggest a...

Dec 13, 2023